While advances have been made treating blood cancers, challenges remain, and several are incurable. In addition, traditional chemotherapy can be highly toxic and carry major side effects.

SLAM Biotherapeutics is an oncology biotech company developing a platform of first-in-class antibodies and ADCs (antibody drug conjugates) that meets this challenge with strong efficacy and a safe tox profile. Their breakthrough antibodies will impact the lives of patients with life-threatening cancers such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and cutaneous T-cell lymphoma (CTCL). SLAM Bio is targeting CD84 which is a member of the signaling lymphocytic activation molecule (SLAM) protein family. They are the first to do this with monoclonal antibodies and ADCs.

SLAM Bio has a broad IP portfolio of 17 antibodies targeting CD84 with issued patents and an exclusive license from City of Hope and The Weizmann Institute. Their lead program is a first-in-class antibody targeting CD84, a cell surface adhesion molecule that is expressed on a spectrum of blood cancers and on immune suppressor cells in the micro-environment of all cancers. They expect to be in the clinic Q4 2025, which is a major inflection point for this drug targeting a $20+ billion market.

SLAM Bio is led by a team with extensive experience in early-stage life science programs with a history of successful exits. They have Dr. Steven Rosen, a giant in cancer, as their co-founder.

Join this online event with SLAM Bio CEO Steve Potts, and Chairman and Co-Founder, Rick Heinick, to hear how their portfolio of novel antibodies has demonstrated promising preclinical results with the potential to curb the growth and spread of a broad spectrum of cancers.